101 related articles for article (PubMed ID: 10646635)
21. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
22. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120.
Bitton N; Verrier F; Debré P; Gorochov G
Eur J Immunol; 1998 Dec; 28(12):4177-87. PubMed ID: 9862354
[TBL] [Abstract][Full Text] [Related]
23. Over-expressing Akt in T cells to resist tumor immunosuppression and increase anti-tumor activity.
Wu Y; Deng Z; Tang Y; Zhang S; Zhang YQ
BMC Cancer; 2015 Aug; 15():603. PubMed ID: 26310246
[TBL] [Abstract][Full Text] [Related]
24. Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
Pameijer CR; Navanjo A; Meechoovet B; Wagner JR; Aguilar B; Wright CL; Chang WC; Brown CE; Jensen MC
Cancer Gene Ther; 2007 Jan; 14(1):91-7. PubMed ID: 17024231
[TBL] [Abstract][Full Text] [Related]
25. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.
Reinhold U; Liu L; Lüdtke-Handjery HC; Heuser C; Hombach A; Wang X; Tilgen W; Ferrone S; Abken H
J Invest Dermatol; 1999 May; 112(5):744-50. PubMed ID: 10233766
[TBL] [Abstract][Full Text] [Related]
26. An EGP-2/Ep-CAM-expressing transgenic rat model to evaluate antibody-mediated immunotherapy.
McLaughlin PM; Kroesen BJ; Dokter WH; van der Molen H; de Groot M; Brinker MG; Kok K; Ruiters MH; Buys CH; de Leij LF
Cancer Immunol Immunother; 1999 Sep; 48(6):303-11. PubMed ID: 10473805
[TBL] [Abstract][Full Text] [Related]
27. Activation of T cells via tumor antigen specific chimeric receptors: the role of the intracellular signaling domain.
Losch FO; Müller R; Mutschler B; Neri D; Natali PG; Reth M; Carsetti R
Int J Cancer; 2003 Jan; 103(3):399-407. PubMed ID: 12471624
[TBL] [Abstract][Full Text] [Related]
28. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells.
Watanabe K; Terakura S; Martens AC; van Meerten T; Uchiyama S; Imai M; Sakemura R; Goto T; Hanajiri R; Imahashi N; Shimada K; Tomita A; Kiyoi H; Nishida T; Naoe T; Murata M
J Immunol; 2015 Feb; 194(3):911-20. PubMed ID: 25520398
[TBL] [Abstract][Full Text] [Related]
29. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
30. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
Mezzanzanica D; Canevari S; Mazzoni A; Figini M; Colnaghi MI; Waks T; Schindler DG; Eshhar Z
Cancer Gene Ther; 1998; 5(6):401-7. PubMed ID: 9917095
[TBL] [Abstract][Full Text] [Related]
31. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
[TBL] [Abstract][Full Text] [Related]
32. Bispecific antibody-mediated target cell-specific costimulation of resting T cells via CD5 and CD28.
Kroesen BJ; Bakker A; van Lier RA; The HT; de Leij L
Cancer Res; 1995 Oct; 55(19):4409-15. PubMed ID: 7545540
[TBL] [Abstract][Full Text] [Related]
33. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
Pulè MA; Straathof KC; Dotti G; Heslop HE; Rooney CM; Brenner MK
Mol Ther; 2005 Nov; 12(5):933-41. PubMed ID: 15979412
[TBL] [Abstract][Full Text] [Related]
34. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
35. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.
Weijtens ME; Willemsen RA; Valerio D; Stam K; Bolhuis RL
J Immunol; 1996 Jul; 157(2):836-43. PubMed ID: 8752936
[TBL] [Abstract][Full Text] [Related]
36. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.
Parker LL; Do MT; Westwood JA; Wunderlich JR; Dudley ME; Rosenberg SA; Hwu P
Hum Gene Ther; 2000 Nov; 11(17):2377-87. PubMed ID: 11096442
[TBL] [Abstract][Full Text] [Related]
37. Use of the EGP-2/Ep-CAM promoter for targeted expression of heterologous genes in carcinoma derived cell lines.
McLaughlin PM; Trzpis M; Kroesen BJ; Helfrich W; Terpstra P; Dokter WH; Ruiters MH; de Leij LF; Harmsen MC
Cancer Gene Ther; 2004 Sep; 11(9):603-12. PubMed ID: 15243630
[TBL] [Abstract][Full Text] [Related]
38. Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody.
Paul S; Bizouarne N; Dott K; Ruet L; Dufour P; Acres RB; Kieny MP
Cancer Gene Ther; 2000 Apr; 7(4):615-23. PubMed ID: 10811480
[TBL] [Abstract][Full Text] [Related]
39. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
[TBL] [Abstract][Full Text] [Related]
40. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.
Hombach A; Hombach AA; Abken H
Gene Ther; 2010 Oct; 17(10):1206-13. PubMed ID: 20555360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
